Comment on “Good Data Science Practice: Moving towards a Code of Practice for Drug Development”

Abstract

We want to congratulate Baillie, Moloney, Mueller, Dorn, Branson, and Ohlssen on a high-impactful article. We sincerely appreciate that Baillie et al. (2022) proposed their definition of data science, which can be tailored to the industry of drug development. They also highlighted issues with scientific practice from five perspectives, leading to a framework for good practice that we would follow in the pharmaceutical industry, should the framework be strengthened by adding one more perspective, the causal perspective.

Acknowledgments

This article was sponsored by AbbVie. AbbVie contributed to the design, research, and interpretation of data, writing, reviewing, and approved the content. All authors are employees of AbbVie Inc. and may own AbbVie stock.